ANTICHOLINESTERASES



INDIRECT ACTING CHOLINOMIMETICS

CHOLINESTERASE INHIBITORS

Dr.Attiya Munir AP Pharmacology

SOURCES: BERTRAM G. KATZUNG BASIC & CLINICAL PHARMACOLOGY 15TH EDITION GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS 13TH EDITION.

LEARNING OBJECTIVES



- At the end of this session, students will be able to:
- Classify indirectly acting cholinomimetics.
- Discuss mechanism of action.
- Describe the organ system effects produced by these drugs.
- Enumerate uses and adverse effects of cholinomimetics.




MOTTO AND VISION



- To impart evidence based research oriented medical education
- To provide best possible patient care
- To inculcate the values of mutual respect and ethical practice of medicine



Prof. Umar's Clinically Oriented Integration Model For Basic Sciences Interactive Lectures



3 rd Year Pharmacology LGIS			
Core Subject – 60%			
Pharmacology			
Horizontal Integration - 10%			
Same Year Subjects	•	Pathology (10%)	
Vertical Integration - 10%			
Clinical Subjects	•	Medicine (10%)	
Spiral Integration – 15%			
Different Year Basic Sciences Subjects	•	Physiology (10%) Biochemistry (5%)	
Vertical Integration – 05%			
Research & Bioethics			

PRE LECTURE ASSESSMENT

1. Which of the following condition limits the use of muscarinic agonists:

- a) Bronchospasm
- b) \uparrow Intraocular pressure
- c) Loss of memory
- d) Muscles weakness
- e) Xerostomia

2. A 45-year-old male patient presents with complaints of dry mouth, blurred vision and difficulty in swallowing. Upon examination, he shows signs of decreased salivation and pupillary dilation. The doctor decides to treat the patient with a drug that increases acetylcholine levels in the synaptic cleft by inhibiting acetylcholinesterase. Which of the following drugs, acting indirectly, would be most appropriate for this patient?

- A) Atropine
- B) Neostigmine
- c) Physostigmine
- D) Tropicamide

- 3. Which of the following cholinergic is used in treatment of Alzheimer's disease;
- a) Acetylcholine
- b) Bethanechol
- c) Edrophonium
- d) Galantamine
- e) Physostigmine

4. A 45-year-old male presents to the emergency department with difficulty breathing, excessive salivation, and muscle weakness after being exposed to an organophosphate pesticide while working in the fields. On examination, he has pinpoint pupils, bradycardia, and muscle fasciculations. The physician suspects poisoning with an anticholinesterase agent. Which of the following is the most appropriate initial treatment for this patient?

- A) Atropine
- B) Pralidoxime (2-PAM)
- c) Physostigmine
- D) Epinephrine
- E) Naloxone

5. A 60-year-old male with a history of myasthenia gravis presents to the emergency department with worsening weakness, double vision, and difficulty swallowing. He reports that his dose of pyridostigmine (an acetylcholinesterase inhibitor used to manage myasthenia gravis) has been recently increased. He appears to be fatigued, and his respiratory rate is elevated. Which of the following is the most likely cause of his symptoms?

- a) Cholinergic crisis
- b) Mysthenia crisis
- c) Organophosphate poisoning

- d) Acute stroke
- e) Drug overdose
- 6. What does the term "aging" refer to in the context of organophosphate poisoning?
- A) The process by which the organophosphate molecule undergoes chemical breakdown, reducing its toxicity.
- B) The irreversible binding of the organophosphate to acetylcholinesterase, making it harder to reverse with pralidoxime.
- c) The process by which acetylcholinesterase becomes more sensitive to organophosphate agents over time.
- D) The acceleration of the body's ability to metabolize organophosphate compounds.
- E) The gradual improvement in acetylcholinesterase activity due to aging of the nerve terminals.

7. A middle age farmer while spraying pesticide suffered diarrhea, urination, miosis,lacrimation,bronchoconstriction, bradycardia, salivation, sweating, muscle weakness & seizures.Which of the following chemical antagonist is used in this medical emergency?

- a) Atropine
- b) Carbachol
- c) Donepezil
- d) Paralidoxime
- e) Rivastigmine

- 8. The mechanism of action of neostigmine in the management of myasthenia gravis?
- A) Neostigmine blocks acetylcholine receptors at the neuromuscular junction.
- B) Neostigmine inhibits acetylcholinesterase, increasing acetylcholine availability at the neuromuscular junction.
- c) Neostigmine increases the release of acetylcholine from presynaptic nerve endings.
- D) Neostigmine enhances the binding of acetylcholine to nicotinic receptors at the neuromuscular junction.
- E) Neostigmine decreases the sensitivity of muscle cells to acetylcholine.

7. A 60-year-old male with glaucoma presents to the ophthalmology clinic for routine follow-up. His (IOP) has been difficult to control with topical medications, and his physician is considering adding another agent. The physician prescribes carbachol.Which of the following is the most likely mechanism of action of carbachol in the treatment of glaucoma?

- A) Carbachol inhibits the production of aqueous humor by the ciliary body.
- B) Carbachol increases the production of aqueous humor by the ciliary body.
- c) Carbachol promotes contraction of the ciliary muscle, increasing the outflow of aqueous humor.
- D) Carbachol blocks the receptors in the trabecular meshwork, reducing resistance to aqueous humor outflow.
- E) Carbachol directly stimulates alpha-adrenergic receptors to reduce aqueous humor
- 8. What is the primary role of pralidoxime in the treatment of organophosphate poisoning?
- A) Pralidoxime acts as a competitive inhibitor of acetylcholinesterase, reducing the breakdown of acetylcholine.
- B) Pralidoxime regenerates acetylcholinesterase by breaking the bond between the organophosphate and the enzyme.
- c) Pralidoxime increases the release of acetylcholine from nerve endings to counteract the effects of poisoning.
- D) Pralidoxime inhibits muscarinic receptors to reverse the symptoms of poisoning.

E) Pralidoxime blocks the binding of organophosphates to muscarinic receptors in the peripheral tissues.

CLASSIFICATION ON THE BASIS OF STRUCTURE

REVERSIBLE

ALCOHOLS

Edrophonium(Quaternary)

CARBAMATES

Tertiary Amines Physostigmine Quaternary Amines Neostigmine Pyridostigmine

CONTINUED....



Tacrine Donepezil Rivastigmine Galantamine

Core subject

IRREVERSIBLE

ORGANOPHOSPHATES Therapeutic use Echothiophate Insecticides Malathion Parathion **Nerve gases** Tabuin Sarin Soman

CONTINUED....

CARBAMATES

Carbaryl Propoxur

Core subject

CLASSIFICATION ON BASIS OF DURATION OF ACTION

SHORT ACTING (5-10MINS) Edrophornium INTERMEDIATE ACTING (3-6HRS)

Neostigmine Physostigmine Pyridostigmine LONGER ACTING (6-8HRS)

Donepezil

Tacrine


VERY LONG ACTING (IRREVERSIBLE)

Insecticides War Gases Ecothiopate

PHARMACOKINECTICS


Indirect-acting, alcohol	
Edrophonium	Highly polar; used IV
	Duration: 5–10 min
Indirect-acting, carbamate	
Neostigmine	Moderately polar but orally active
	Duration: 2–4 h
Pyridostigmine	Moderately polar but orally active
	Duration: 4–8 h
Physostigmine	Lipid soluble; can be used topically in the eye
	Duration: 2–4 h Core subject 15


Indirect-acting, organophosphate	
Parathion	Highly lipid-soluble
Malathion	Highly lipid-soluble but metabolized to inactive products in mammals and birds
Sarin, tabun, others	Like parathion but more rapid action Core Subject



Core subject

Medscape® www.medscape.com





Organ system effects


- * G.I.T
- URINARY BLADDER
- *** EXOCRINE GLANDS**
- LUNGS
- * C.V.S
- **SKELETAL MUSCLES**


Therapeutic Uses of Inhibitors of Acetylcholinesterase

- 1. Glaucoma (wide angle)
- 2. Atony of the bladder or GIT (after surgery).
- Intoxication by antimuscarinic agents, tricyclic antidepressants (TCA's) or phenothiazines (use physostigmine)
- Recovery of neuromuscular function after competitive blockade of Nm receptor of skeletal muscle fibers
- 5. Myasthenia gravis

MYASTHENIA GRAVIS

- Definition
- MOA
- Signs and symptoms
- Diagnosis
- Difference between myasthenic crisis and cholinergic crisis
- Management
















DIAGNOSIS

- EDROPHONIUM is used as diagnosis for myasthenia gravis.(Tensilon test)
- 2mg dose is injected iv after baseline muscle strength has been measured.
- If nothing untoward happen in 45 secs, an additional 8mg may be injected.

SCERATION-PATHOLOGY

HORIZON

If the patient has myasthenia gravis, an improvement in muscle strength that lasts about 5mins can usually be observed.



ine common early signs

edrophonium chloride

How to differentiate between Myasthenic crisis & Cholinergic crisis

Myathenic crisis

- Skeletal muscle weakness due to untreated or inadequately treated myasthenia Gravis.
- **Neostigmine** : Improved muscle strength

Cholinergic crisis Skeletal muscle weakness due to over treated myasthenia gravis i.e. depolarization block.

- Neostigmine: No effect or increase muscle weakness
- Treatment: Decrease the dose of neostigmine

TREATMENT

- Indirectly acting cholinesterase inhibitors
- Neostigmine
- Pyridostigmine
- Corticosteriods
- Plasmapheresis
- Thymectomy

ADVERSE EFFECTS


ORGANOPHOSPHOROUS POISONING


Features


- Diarrhea
- Urination
- Muscle weakness/miosis
- Bradycardia
- Bronchoconstriction
- Emesis
- Lacrimation
- Salivation/sweating
 - Convulsions, coma

TREATMENT


- Maintenance of vitals
- Decontamination
- ✓ Atropine
- Diazepam
- Cholinestrase enzyme regenerators
 - Pralidoxime Diacetylmonoxime








The rate of aging is unique for each organophosphate compound, and can occur over minutes to days depending on the agent



Pralidoxime (2-PAM) prevents aging

& regenerates AChE



Modifed from: CDC Case Studies in Environmental Medicine http://www.atsdr.cdc.gov/csem/csem.asp?csem=11&po=23³¹

Chronic exposure

- Triorthocresyl phosphate
- Delayed neuropathy associated with demyelination of axons
- Intermediate syndrome
- Prophlaxsis of chemical warfare
- Pyridostigmine

RESEARCH

 Žnidaršic, N., Štrbenc, M., Grgurevic, N. and Snoj, T., 2023. Potential revival of cholinesterase inhibitors as drugs in veterinary medicine.

ARTIFICIAL INTELLIGENCE

Nour H, Abdou A, Belaidi S, Jamal J, Elmakssoudi A, Dakir M, Chtita S. Discovery of promising cholinesterase inhibitors for Alzheimer's disease treatment through DFT, docking, and molecular dynamics studies of eugenol derivatives. Journal of the Chinese Chemical Society. 2022 Sep;69(9):1534–51.